Efficacy analysis of a bismuth-containing quadruple therapy with vonoprazan for Helicobacter pylori infection
Abstract
OBJECTIVE: To retrospectively analyze the efficacy and safety of a bismuth-containing quadruple regimen with vonoprazan (VPZ) in the initial eradication of Helicobacter pylori (Hp) infection and to identify influencing factors.
METHODS: A total of 1017 treatment-naïve patients with Hp infection, who received a 14-day bismuth-containing quadruple therapy with vonoprazan (VPZ+ bismuth potassium citrate + two antibiotics) between January 2023 and December 2024 at Zhejiang Hospital, were enrolled. Based on actual antibiotic usage, patients were categorized into seven subgroups. Hp eradication rates and influencing factors were analyzed.
RESULTS: The overall treatment success rate of the VPZ-based bismuth quadruple therapy was 90.9% (924/1017). The eradication rates for each subgroup were: Clarithromycin + Amoxicillin 93.3% (714/765), Furazolidone + Amoxicillin 93.5% (87/93), Clarithromycin + Furazolidone 73.7% (42/57), Levofloxacin + Cefuroxime 81.3% (39/48), Clarithromycin + Cefuroxime 100% (24/24), Levofloxacin + Clarithromycin 80.0% (12/15), and Levofloxacin + Furazolidone 40.0% (6/15). Univariate analysis revealed a statistically significant difference in eradication rates among the different treatment regimens (p = 0.002). Binary logistic regression analysis confirmed that the treatment regimen was an independent factor affecting eradication outcome (p = 0.008). Factors such as age, sex, smoking, and alcohol consumption showed no significant correlation with treatment…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.